Singapore - Merck to invest $800 million
Merck’s Singapore unit, Merck Sharpe & Dohme (MSD) has announced that it will invest US$800 million over the next 10 years in Singapore to upgrade its manufacturing facilities, expand its biotech activities, and design new processes for the commercial production of new products. As part of an agreement between Merck and Singapore’s Economic Development Board (EDB), Merck will invest more than US$250 million to expand its current production facilities in Tuas. It currently manufactures 15 products for the global markets at its two facilities in Singapore.
The company has also committed to spending an additional S$700 million on local research activities. It plans a Centre of Excellence, to possibly explore new drug delivery platforms such as through the nose and lungs. Singapore is also likely to host pilot production and commercial manufacturing of new products at a later stage.
Another focus for Merck will be the development of skills and the broadening of technical expertise among its Singapore-based employees. This will be done through collaborations with local universities and training opportunities at its overseas facilities.
Merck set up its manufacturing operations in 1996 and has since invested close to US$1.5billion in Singapore. The company currently employs about 1,500 employees in its Singapore-based organisations. These include its regional operation headquarters, marketing and sales organisations and its Translational Medicines Research Centre
For further information please click here
Other news stories
Please click here to be taken to the lastest report on Asia from the IMF - June 2010